Advanced search
1 file | 92.74 KB

Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes versus mono-components in COPD in two 1-year studies

(2014) THORAX. 69(suppl. 2). p.A188-A189
Author
Organization

Downloads

  • Buhl Safety of once daily tiotropium pp189-190.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 92.74 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Buhl, R, Eric Derom, G Ferguson, E Pizzichini, J Reid, H Watz, L Groenke, et al. 2014. “Once-daily Tiotropium and Olodaterol Fixed-dose Combination via the Respimat® Improves Outcomes Versus Mono-components in COPD in Two 1-year Studies.” In Thorax, 69:A188–A189.
APA
Buhl, R, Derom, E., Ferguson, G., Pizzichini, E., Reid, J., Watz, H., Groenke, L., et al. (2014). Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes versus mono-components in COPD in two 1-year studies. THORAX (Vol. 69, pp. A188–A189). Presented at the Meeting of the British Thoracic Society.
Vancouver
1.
Buhl R, Derom E, Ferguson G, Pizzichini E, Reid J, Watz H, et al. Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes versus mono-components in COPD in two 1-year studies. THORAX. 2014. p. A188–A189.
MLA
Buhl, R et al. “Once-daily Tiotropium and Olodaterol Fixed-dose Combination via the Respimat® Improves Outcomes Versus Mono-components in COPD in Two 1-year Studies.” Thorax. Vol. 69. 2014. A188–A189. Print.
@inproceedings{6908614,
  articleno    = {abstract P254},
  author       = {Buhl, R and Derom, Eric and Ferguson, G and Pizzichini, E and Reid, J and Watz, H and Groenke, L and Hamilton, A and Tetzlaff, K and Korducki, L and Huisman, H and Waitere-Wijker, S and Maltais, F},
  booktitle    = {THORAX},
  issn         = {0040-6376},
  language     = {eng},
  location     = {London, UK},
  number       = {suppl. 2},
  pages        = {abstract P254:A188--abstract P254:A189},
  title        = {Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat® improves outcomes versus mono-components in COPD in two 1-year studies},
  url          = {http://dx.doi.org/10.1136/thoraxjnl-2014-206260.382},
  volume       = {69},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: